Beigene Co. Ltd., of Beijing, appointed RuiRong Yuan chief medical officer and president of global clinical development. Yuan will be responsible for driving the development of the company's portfolio of drug candidates through to regulatory approval, as well as contributing to design and providing overall medical and safety oversight for oncology clinical trials. Read More
HONG KONG – Sichuan-based Revotek Co., a Chinese company claiming to be the first in the world able to produce blood vessels using 3-D bioprinting technology, said it is now planning to combine the technology with a cloud-computing platform. Read More
NEW DELHI – Indian biopharmaceutical companies are stepping up their forays into the biosimilars arena, with two firms announcing plans to expand their activities in the space over the past couple of weeks. Read More
HONG KONG – Start-up antibody-focused Mabspace Biosciences Co. Ltd. has secured $15 million in series A financing with Lilly Asia Ventures to help move two of its cancer candidates into clinical studies and further its antibody pipeline. Read More
SHANGHAI – Tianjin Cansino Inc., the company behind China's phase II Ebola vaccine, has received a $30 million investment from well-respected health care venture firms Qiming Venture Partners and Lilly Asia Ventures. It marks the second venture capital round for the 6-year-old company; in 2013, it accepted $10 million in a round led by Lilly Asia Ventures. (See BioWorld Today, Oct. 13, 2013.) Read More
HONG KONG – Celltrion Inc. had a seven-year partnership with Pfizer Inc.'s new subsidiary, Hospira Inc., to develop two biosimilar assets, but those ties were severed last week when Pfizer cut loose the rights for the two assets, saying that it plans to focus on a pipeline of in-house developed biosimilars. Read More
